First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302.
사설/논평
0/5 보강
APA
Liedberg F, Ståhl O, Bobjer J (2026). First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302.. Translational andrology and urology, 15(1), 8. https://doi.org/10.21037/tau-2025-733
MLA
Liedberg F, et al.. "First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302.." Translational andrology and urology, vol. 15, no. 1, 2026, pp. 8.
PMID
41658467 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma.
- Carbon ion radiotherapy optimization techniques for pancreatic cancer: accounting for the effect of bowel gas variation.
- Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer.
- Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know?
- Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.
- Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis.